JERSEY CITY, N.J., April 15, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced results showing evidence of activity of the company's lead product candidate, ibrexafungerp, against fungal infections in multiple settings and indications. These include case studies showing treatment with oral ibrexafungerp resulting in full clearance of Candida auris infections. The findings were described in one oral presentation and five poster presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 13-16, 2019, in Amsterdam, Netherlands.
"We are encouraged by the data shared at ECCMID 2019 and ibrexafungerp's potential to be a new treatment in the fight against difficult-to-treat and resistant fungal infections," said David Angulo, M.D., Chief Medical Officer of SCYNEXIS. "This additional evidence of clinical activity of ibrexafungerp in a variety of infection types further highlights its versatility and its potential to address unmet needs. We are heartened by the recent attention given to Candida auris, as we believe that increased awareness combined with new treatments are the keys to success in the fight against this serious global health threat."
The five ibrexafungerp poster presentations are as follows:
- Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078) from the CARES Study (#L0028 - Deven Juneja, MD)
- Favourable Clinical Outcome of Two Patients with Candida spp. Spondylodiscitis Treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study (#L0033 - Philipp Koehler, MD)
- Use of Ibrexafungerp (formerly SCY-078) to Treat Severe Azole-refractory Oesophageal Candidiasis: A Case Report from the FURI Study (#P0125 - Jose Vazquez, MD)
- Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model (#O0740 - Annie Lee, PhD)
- Efficacy of Ibrexafungerp (formerly SCY-078) against Pneumocystis Pneumonia in a Murine Therapeutic Model (#O0733 - Stephen Barat, PhD)
One oral presentation (#L0010), showcasing results from the first interim analysis of 20 patients with various Candida infections from the FURI study will be given by Dr. Oliver Cornely on Tuesday, April 16, from 11:00-12:00 CET.
Conference Call Details
SCYNEXIS will hold a conference call today at 4:15 p.m. ET to discuss the ibrexafungerp data presented at ECCMID 2019. SCYNEXIS management will be joined by the following global thought leaders:
- Oliver Cornely, M.D., Professor of Internal Medicine and Medical Director, Clinical Trials Center Cologne at the University of Cologne in Germany;
- Jose Vazquez, M.D., Division Chief and Professor of Medicine and Infectious Diseases, Augusta University, Georgia; and
- Deven Juneja, M.D., Assistant Professor, Department of Critical Care at the Max Super Specialty Hospital in New Delhi, India. Due to prior commitments, Dr. Juneja is unable to join today's call but kindly recorded his remarks.
U.S. Dial-in Number: 844-309-3707
International Dial-In Number: 661-378-9467
Conference ID: 2870577
The slide and audio webcast can be accessed by visiting the Investors section of the Company's website at http://ir.scynexis.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company's website for 30 days.
Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an investigational antifungal agent and the first representative of a novel family of compounds referred to as "fungerps" (antifungal triterpenoids). This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations. Ibrexafungerp is currently in clinical development for the treatment of several serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections. It has demonstrated broad spectrum antifungal activity, in vitro and in vivo, against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains. The FDA has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for the formulations of ibrexafungerp for the indications of invasive candidiasis (IC) (including candidemia), invasive aspergillosis (IA) and VVC, and has granted Orphan Drug Designation for the IC and IA indications. Ibrexafungerp is formerly known as SCY-078.
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida, Aspergillus and Pneumocystis species. For more information, visit www.scynexis.com.
Forward Looking Statement
Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in SCYNEXIS's ability to successfully develop and obtain FDA approval for ibrexafungerp. These and other risks are described more fully in SCYNEXIS's filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K under the caption "Risk Factors" and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
George E. MacDougall
SOURCE SCYNEXIS, Inc.